1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Plexiform Neurofibroma: new trials by email Literature Review of Plexiform Neurofibroma trials Research Report on Plexiform Neurofibroma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group (Group B): Placebo, orally, once daily; - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 3 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 167 | 2023-06-20 | 2025-03-06 |
Neurofibroma, Plexiform (1) · Neurofibromatosis 1 (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Heredodegenerative Disorders, Nervous System (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Nerve Tissue (1) · Neoplastic Syndromes, Hereditary (1) · Nerve Sheath Neoplasms (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1) · Neurocutaneous Syndromes (1) · Neurodegenerative Diseases (1) · Neurofibroma (1) · Neurofibromatoses (1) · Neuromuscular Diseases (1)
Control Groups (1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (1)
China (1)
Wenbin Li, MD (1)